Cagrilintide Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide PharmaLive Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as